Integrum AB Series B (ST:INTEG-B) — Market Cap & Net Worth
Market Cap & Net Worth: Integrum AB Series B (INTEG-B)
Integrum AB Series B (ST:INTEG-B) has a market capitalization of $26.19 Million (Skr243.36 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #24318 globally and #466 in its home market, demonstrating a 5.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Integrum AB Series B's stock price Skr9.35 by its total outstanding shares 26027910 (26.03 Million). Also see total assets of Integrum AB Series B for a full breakdown of the balance sheet.
Integrum AB Series B Market Cap History: 2017 to 2026
Integrum AB Series B's market capitalization history from 2017 to 2026. Data shows change from $87.93 Million to $26.19 Million (-7.90% CAGR). Also see INTEG-B cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Integrum AB Series B is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.23 Billion | 0.17% | #92 of 281 |
Weight: Integrum AB Series B's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Integrum AB Series B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Integrum AB Series B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check INTEG-B live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.33x
Integrum AB Series B's market cap is 0.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $87.93 Million | $15.17 Million | -$18.36 Million | 5.79x | N/A |
| 2018 | $23.08 Million | $22.45 Million | -$24.58 Million | 1.03x | N/A |
| 2019 | $28.01 Million | $26.75 Million | -$15.69 Million | 1.05x | N/A |
| 2020 | $122.96 Million | $43.09 Million | -$2.14 Million | 2.85x | N/A |
| 2021 | $201.67 Million | $55.72 Million | $21.27 Million | 3.62x | 9.48x |
| 2022 | $96.64 Million | $74.27 Million | -$16.18 Million | 1.30x | N/A |
| 2023 | $127.87 Million | $104.12 Million | $4.03 Million | 1.23x | 31.71x |
| 2024 | $51.26 Million | $91.10 Million | -$30.85 Million | 0.56x | N/A |
| 2025 | $30.14 Million | $91.39 Million | -$46.34 Million | 0.33x | N/A |
Competitor Companies of INTEG-B by Market Capitalization
Companies near Integrum AB Series B in the global market cap rankings as of September 19, 2026. Review how tangible is Integrum AB Series B's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Integrum AB Series B by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Integrum AB Series B Historical Marketcap From 2017 to 2026
Between 2017 and today, Integrum AB Series B's market cap moved from $87.93 Million to $ 26.19 Million, with a yearly change of -7.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr26.19 Million | -13.10% |
| 2025 | Skr30.14 Million | -41.20% |
| 2024 | Skr51.26 Million | -59.91% |
| 2023 | Skr127.87 Million | +32.32% |
| 2022 | Skr96.64 Million | -52.08% |
| 2021 | Skr201.67 Million | +64.01% |
| 2020 | Skr122.96 Million | +339.00% |
| 2019 | Skr28.01 Million | +21.36% |
| 2018 | Skr23.08 Million | -73.75% |
| 2017 | Skr87.93 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Integrum AB Series B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.19 Million USD |
| MoneyControl | $26.19 Million USD |
| MarketWatch | $26.19 Million USD |
| marketcap.company | $26.19 Million USD |
| Reuters | $26.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Integrum AB Series B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoidi… Read more